GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » Gross Margin %
中文

Neurocrine Biosciences (BSP:N1BI34) Gross Margin % : 98.35% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Neurocrine Biosciences Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Neurocrine Biosciences's Gross Profit for the three months ended in Dec. 2023 was R$2,483 Mil. Neurocrine Biosciences's Revenue for the three months ended in Dec. 2023 was R$2,524 Mil. Therefore, Neurocrine Biosciences's Gross Margin % for the quarter that ended in Dec. 2023 was 98.35%.


The historical rank and industry rank for Neurocrine Biosciences's Gross Margin % or its related term are showing as below:

BSP:N1BI34' s Gross Margin % Range Over the Past 10 Years
Min: 97.9   Med: 98.91   Max: 99.22
Current: 97.9


During the past 13 years, the highest Gross Margin % of Neurocrine Biosciences was 99.22%. The lowest was 97.90%. And the median was 98.91%.

BSP:N1BI34's Gross Margin % is ranked better than
99.19% of 991 companies
in the Drug Manufacturers industry
Industry Median: 46.77 vs BSP:N1BI34: 97.90

Neurocrine Biosciences had a gross margin of 98.35% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Neurocrine Biosciences was -0.20% per year.


Neurocrine Biosciences Gross Margin % Historical Data

The historical data trend for Neurocrine Biosciences's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Gross Margin % Chart

Neurocrine Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 99.06 99.03 98.74 98.44 97.90

Neurocrine Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.13 97.98 97.46 97.75 98.35

Competitive Comparison of Neurocrine Biosciences's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Gross Margin % falls into.



Neurocrine Biosciences Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Neurocrine Biosciences's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=9051.9 / 9246.413
=(Revenue - Cost of Goods Sold) / Revenue
=(9246.413 - 194.522) / 9246.413
=97.90 %

Neurocrine Biosciences's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=2482.7 / 2524.377
=(Revenue - Cost of Goods Sold) / Revenue
=(2524.377 - 41.648) / 2524.377
=98.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Neurocrine Biosciences  (BSP:N1BI34) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Neurocrine Biosciences had a gross margin of 98.35% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Neurocrine Biosciences Gross Margin % Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences (BSP:N1BI34) Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (BSP:N1BI34) Headlines

No Headlines